The Programme

Dah Sing Bank and Friends of the Earth (HK) Jointly Present Retail and E-Commerce ESG Forum for SMEs

Retrieved on: 
Wednesday, September 21, 2022

HONG KONG, Sept 21, 2022 - (ACN Newswire) - The second industry forum (the "Forum") under the SME ESG Best Practices Recognition Programme ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").

Key Points: 
  • HONG KONG, Sept 21, 2022 - (ACN Newswire) - The second industry forum (the "Forum") under the SME ESG Best Practices Recognition Programme ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").
  • Dah Sing Bank, Limited ("Dah Sing Bank") is a wholly-owned subsidiary of Dah Sing Banking Group Limited (HKG:2356) which is listed on the Hong Kong Stock Exchange.
  • In addition to its Hong Kong banking operations, Dah Sing Bank also has wholly-owned subsidiaries including Dah Sing Bank (China) Limited, Banco Comercial de Macau, S.A., and OK Finance Limited.
  • Dah Sing Bank and Friends of the Earth (HK) Jointly Present:
    Industry Forums / Programme Application Opens: 27 June 2022 / 21 September 2022
    Online Questionnaire Completion & Supporting Documents Submission: Until 31 December 2022 / Until 28 February 2023

Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim

Retrieved on: 
Thursday, August 4, 2022

Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.

Key Points: 
  • Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.
  • Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
  • Olorofim has received orphan drug status from the European Medicines Agency for the treatment of invasive aspergillosis and invasive scedosporiosis.
  • Olorofim has also received orphan drug status from the FDA for the treatment of coccidioidomycosis scedosporiosis, and invasive aspergillosis.

Dah Sing Bank and Friends of the Earth (HK) Jointly Present Property and Construction Industry ESG Forum for SMEs

Retrieved on: 
Monday, June 27, 2022

HONG KONG, June 27, 2022 - (ACN Newswire) - The first industry forum ("the Forum") under the "SME ESG Best Practices Recognition Programme" ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").

Key Points: 
  • HONG KONG, June 27, 2022 - (ACN Newswire) - The first industry forum ("the Forum") under the "SME ESG Best Practices Recognition Programme" ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").
  • ESG implementation may become one of the ways for SMEs to overcome adversity in a down market.
  • Dah Sing Bank, Limited ("Dah Sing Bank") is a wholly-owned subsidiary of Dah Sing Banking Group Limited (HKG:2356) which is listed on the Hong Kong Stock Exchange.
  • In addition to its Hong Kong banking operations, Dah Sing Bank also has wholly-owned subsidiaries including Dah Sing Bank (China) Limited, Banco Comercial de Macau, S.A., and OK Finance Limited.

Dah Sing Bank and Friends of the Earth (HK) Jointly Present: The SME ESG Best Practices Recognition Programme

Retrieved on: 
Wednesday, June 8, 2022

HONG KONG, June 8, 2022 - (ACN Newswire) - Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) have jointly launched the "SME ESG Best Practices Recognition Programme" ("the Programme") today.

Key Points: 
  • HONG KONG, June 8, 2022 - (ACN Newswire) - Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) have jointly launched the "SME ESG Best Practices Recognition Programme" ("the Programme") today.
  • The Programme encourages SMEs to adopt best practices in environmental, social and governance (ESG), enhancing their competitiveness while achieving sustainable development.
  • Ms. Phoebe Wong, Deputy Chief Executive, Senior Executive Director, Group Head of Personal Banking of Dah Sing Bank, said, "Our Bank is committed to supporting SMEs.
  • Dah Sing Bank, Limited ("Dah Sing Bank") is a wholly-owned subsidiary of Dah Sing Banking Group Limited (HKG:2356) which is listed on the Hong Kong Stock Exchange.

Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund

Retrieved on: 
Thursday, October 14, 2021

Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.

Key Points: 
  • Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
  • Rectify plans to use this financing to fund the company through its first human proof-of-concept (POC) studies.
  • We founded Rectify to deliver life-changing therapies to patients with serious genetic diseases, said Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture.
  • Jonathan Moore, Ph.D., Chief Scientific Officer, founded Rectify with Atlas Venture in 2020.

Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2)

Retrieved on: 
Wednesday, October 6, 2021

PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential as a broad-spectrum antiviral drug targeting RNA viruses.

Key Points: 
  • PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential as a broad-spectrum antiviral drug targeting RNA viruses.
  • This multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate safety and efficacy of PJS-539 in patients recently diagnosed with COVID-19.
  • The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and anti-viral medications.
  • Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection and replication of SARS-CoV-2 and other RNA viruses.

Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development of antibody-based medicines for the treatment of diseases caused by oxidative stress

Retrieved on: 
Thursday, September 16, 2021

Based on a body of research spanning over 40 years published in a range of high profiles scientific papers authored by Profs.

Key Points: 
  • Based on a body of research spanning over 40 years published in a range of high profiles scientific papers authored by Profs.
  • Witztum and Tsimikas, Oxitope is dedicated to the discovery and development of medicines that prevent, halt, or reverse acute and chronic diseases driven by inflammation and cell death as a result of oxidative stress.
  • Founded in 2020, Oxitope Pharma B.V. is a Dutch biopharmaceutical start-up dedicated to the discovery and development of medicines for the treatment of inflammatory, fibrotic and cardiovascular diseases caused by oxidative stress.
  • Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.